RCS - Graft Polymer (UK) - Non Regulatory-Interview with Dennis Purcell

Solvonis Therapeutics

26/09/2024 12:40

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240926:nRSZ8497Fa&default-theme=true

RNS Number : 8497F  Graft Polymer (UK) PLC  26 September 2024

RNS Reach - non-regulatory announcement

 

 

26 September 2024

Graft Polymer (UK) Plc

(the "Company")

 

Proactive Investors interview with Dennis Purcell

 

Graft Polymer (UK) PLC (LON: GPL), an innovative biotechnology company focused
on co-developing therapeutics for mental health disorders, is pleased to note
an interview on Proactive Investors with the Company's new Chairman, Dennis
Purcell.  Mr Purcell's appointment was announced earlier today.

 

The interview and accompanying article can be viewed at Proactive Investors:
Graft Polymer UK appoints biotechnology industry leader Dennis Purcell as
Chairman
(https://www.proactiveinvestors.co.uk/companies/news/1057000/graft-polymer-uk-appoints-biotechnology-industry-leader-dennis-purcell-as-chairman-1057000.html)
.

 

 

 

Enquiries:

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director.
anthonytennyson@graftpolymer.co.uk

 

Allenby Capital (Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc is an innovative biotechnology company focused on
developing intellectual property relating to the treatment of mental health
and substance use disorders, and the co-development of therapeutics for mental
health disorders.  Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on trauma-related
mental health disorders, such as PTSD, which affects approximately 13 million
adults in the U.S. and 20 million in US, UK, and key EU markets.

 

For more information, please visit www.graftpolymer.co.uk.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKABNDBKDOCB